CY1119916T1 - Ανοσογονικη συνθεση - Google Patents
Ανοσογονικη συνθεσηInfo
- Publication number
- CY1119916T1 CY1119916T1 CY20181100188T CY181100188T CY1119916T1 CY 1119916 T1 CY1119916 T1 CY 1119916T1 CY 20181100188 T CY20181100188 T CY 20181100188T CY 181100188 T CY181100188 T CY 181100188T CY 1119916 T1 CY1119916 T1 CY 1119916T1
- Authority
- CY
- Cyprus
- Prior art keywords
- seq
- fragment
- polypeptide
- immune composition
- toxin
- Prior art date
Links
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 210000004899 c-terminal region Anatomy 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 241000193163 Clostridioides difficile Species 0.000 abstract 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 abstract 1
- 101710182223 Toxin B Proteins 0.000 abstract 1
- 101710182532 Toxin a Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Η παρούσα εφεύρεση αφορά σε μία ανοσογονική σύνθεση περιλαμβάνουσα ένα θραύσμα του C τερματικού πεδίου της τοξίνης Α και ένα θραύσμα του C τερματικού πεδίου τοξίνης Β από Clostridium difficile, ιδιαιτέρως δε η εφεύρεση αφορά σε μία ανοσογονική σύνθεση περιλαμβάνουσα ένα πρώτο πολυπεπτίδιο και ένα δεύτερο πολυπεπτίδιο όπου το πρώτο πολυπεπτίδιο περιλαμβάνει: (i) SEQ ID NO: 1, (ii) παραλλαγή της SEQ ID NO: 1 που έχει τουλάχιστον 90%, 95%, 98%, 99% ή 100% ταυτότητα προς SEQ ID NO: 1, ή (iii) θραύσμα από τουλάχιστον 250, 280 ή 300 αμινοξέα της SEQ ID NO: 1, και όπου το δεύτερο πολυπεπτίδιο περιλαμβάνει: (iv) SEQ ID NO: 2, (ν) παραλλαγή της SEQ ID NO: 2 που έχει τουλάχιστον 80%, 90%, 95%, 98%, 99% ή 100% ταυτότητα προς SEQ ID NO: 2, ή (vi) θραύσμα από τουλάχιστον 250, 280, 300, 350, 400, 450, 500, 550 ή 600 αμινοξέα της SEQ ID NO: 2.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490707P | 2011-05-27 | 2011-05-27 | |
| US201161490716P | 2011-05-27 | 2011-05-27 | |
| US201161490734P | 2011-05-27 | 2011-05-27 | |
| PCT/EP2012/059793 WO2012163811A1 (en) | 2011-05-27 | 2012-05-25 | Immunogenic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119916T1 true CY1119916T1 (el) | 2018-06-27 |
Family
ID=46168484
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100158T CY1118599T1 (el) | 2011-05-27 | 2017-02-03 | Ανοσογονος συνθεση |
| CY20181100188T CY1119916T1 (el) | 2011-05-27 | 2018-02-15 | Ανοσογονικη συνθεση |
| CY20191100909T CY1121936T1 (el) | 2011-05-27 | 2019-08-27 | Ανοσογονικη συνθεση |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100158T CY1118599T1 (el) | 2011-05-27 | 2017-02-03 | Ανοσογονος συνθεση |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100909T CY1121936T1 (el) | 2011-05-27 | 2019-08-27 | Ανοσογονικη συνθεση |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US9290565B2 (el) |
| EP (6) | EP2714911B1 (el) |
| JP (3) | JP2014516532A (el) |
| KR (1) | KR102014502B1 (el) |
| CN (3) | CN103732750A (el) |
| BR (2) | BR112013030395B1 (el) |
| CA (2) | CA2837393A1 (el) |
| CY (3) | CY1118599T1 (el) |
| DK (4) | DK2714910T3 (el) |
| EA (1) | EA030898B1 (el) |
| ES (4) | ES2660468T3 (el) |
| FI (1) | FI3564378T3 (el) |
| HR (4) | HRP20231749T1 (el) |
| HU (4) | HUE064492T2 (el) |
| IL (1) | IL229529B2 (el) |
| LT (4) | LT2714911T (el) |
| ME (1) | ME02600B (el) |
| MX (1) | MX346200B (el) |
| PL (4) | PL3564378T3 (el) |
| PT (4) | PT3564378T (el) |
| RS (1) | RS55605B1 (el) |
| SG (1) | SG195037A1 (el) |
| SI (4) | SI3138916T1 (el) |
| SM (2) | SMT201700110T1 (el) |
| WO (3) | WO2012163811A1 (el) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103957931B (zh) | 2010-09-03 | 2017-10-24 | 瓦尔内瓦奥地利有限责任公司 | 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途 |
| AR086199A1 (es) | 2011-04-22 | 2013-11-27 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos |
| IN2014CN04071A (el) | 2011-12-08 | 2015-10-23 | Novartis Ag | |
| BR122016023101B1 (pt) * | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| LT3513806T (lt) | 2012-12-05 | 2023-04-11 | Glaxosmithkline Biologicals Sa | Imunogeninė kompozicija |
| CN105451762A (zh) * | 2013-04-22 | 2016-03-30 | 俄克拉荷马州大学评议会 | 艰难梭菌疫苗及使用方法 |
| ES2870506T3 (es) | 2015-02-19 | 2021-10-27 | Immune Biosolutions Inc | Antígeno y anticuerpo del epítopo de las toxinas a y/o b de clostridium difficile, y sus usos farmacéuticos |
| JP7426953B2 (ja) | 2018-06-19 | 2024-02-02 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
| WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
| WO2023232901A1 (en) | 2022-06-01 | 2023-12-07 | Valneva Austria Gmbh | Clostridium difficile vaccine |
| WO2024160901A1 (en) | 2023-02-02 | 2024-08-08 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| HUT78048A (hu) * | 1994-10-24 | 1999-07-28 | Ophidian Pharmaceuticals, Inc. | A C. difficile által okozott betegség kezelésére és megelőzésére szolgáló vakcina és antitoxin |
| ATE195878T1 (de) * | 1995-07-07 | 2000-09-15 | Oravax Inc | Toxine und toxoide von clostridium difficile als schleimhautadjuvans |
| EP2502998A3 (en) * | 1999-04-09 | 2013-02-27 | Intercell USA, Inc. | Recombinant toxin A/ToxinB vaccine against clostridium difficile |
| AU781027B2 (en) | 1999-04-09 | 2005-04-28 | Department Of Health & Human Services | Recombinant toxin a protein carrier for polysaccharide conjugate vaccines |
| AU2001251013A1 (en) | 2000-03-28 | 2001-10-08 | Diadexus, Inc. | Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer |
| EP2318515A4 (en) | 2008-08-06 | 2012-11-14 | Emergent Product Dev Uk Ltd | DIFFICULT CLOSTRIDIUM VACCINES, AND METHODS OF USE |
| US10046040B2 (en) | 2009-11-16 | 2018-08-14 | University Of Maryland, Baltimore | Multivalent live vector vaccine against Clostridium difficile-associated disease |
| CN103957931B (zh) * | 2010-09-03 | 2017-10-24 | 瓦尔内瓦奥地利有限责任公司 | 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途 |
| GB201016742D0 (en) * | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
-
2012
- 2012-05-25 CN CN201280037466.8A patent/CN103732750A/zh active Pending
- 2012-05-25 WO PCT/EP2012/059793 patent/WO2012163811A1/en active Application Filing
- 2012-05-25 SI SI201231642T patent/SI3138916T1/sl unknown
- 2012-05-25 PL PL19179871.9T patent/PL3564378T3/pl unknown
- 2012-05-25 CA CA2837393A patent/CA2837393A1/en not_active Abandoned
- 2012-05-25 SI SI201231247T patent/SI2714910T1/en unknown
- 2012-05-25 EP EP12726374.7A patent/EP2714911B1/en not_active Revoked
- 2012-05-25 DK DK12724950.6T patent/DK2714910T3/en active
- 2012-05-25 EP EP18150735.1A patent/EP3327126A1/en not_active Withdrawn
- 2012-05-25 ME MEP-2017-26A patent/ME02600B/me unknown
- 2012-05-25 PL PL16193340T patent/PL3138916T3/pl unknown
- 2012-05-25 LT LTEP12726374.7T patent/LT2714911T/lt unknown
- 2012-05-25 US US14/122,690 patent/US9290565B2/en not_active Expired - Fee Related
- 2012-05-25 CN CN201710239709.0A patent/CN107098977A/zh active Pending
- 2012-05-25 SM SM20170110T patent/SMT201700110T1/it unknown
- 2012-05-25 BR BR112013030395-6A patent/BR112013030395B1/pt active IP Right Grant
- 2012-05-25 CA CA2837395A patent/CA2837395C/en active Active
- 2012-05-25 DK DK16193340.3T patent/DK3138916T3/da active
- 2012-05-25 ES ES12724950.6T patent/ES2660468T3/es active Active
- 2012-05-25 LT LTEP16193340.3T patent/LT3138916T/lt unknown
- 2012-05-25 LT LTEP19179871.9T patent/LT3564378T/lt unknown
- 2012-05-25 EP EP12724950.6A patent/EP2714910B1/en active Active
- 2012-05-25 PL PL12726374T patent/PL2714911T3/pl unknown
- 2012-05-25 LT LTEP12724950.6T patent/LT2714910T/lt unknown
- 2012-05-25 DK DK19179871.9T patent/DK3564378T5/da active
- 2012-05-25 MX MX2013013924A patent/MX346200B/es active IP Right Grant
- 2012-05-25 SG SG2013085386A patent/SG195037A1/en unknown
- 2012-05-25 EP EP23205566.5A patent/EP4296361A3/en active Pending
- 2012-05-25 EP EP16193340.3A patent/EP3138916B1/en not_active Revoked
- 2012-05-25 JP JP2014511895A patent/JP2014516532A/ja active Pending
- 2012-05-25 RS RS20170051A patent/RS55605B1/sr unknown
- 2012-05-25 PT PT191798719T patent/PT3564378T/pt unknown
- 2012-05-25 US US14/122,345 patent/US9409974B2/en active Active
- 2012-05-25 PL PL12724950T patent/PL2714910T3/pl unknown
- 2012-05-25 SI SI201232050T patent/SI3564378T1/sl unknown
- 2012-05-25 PT PT16193340T patent/PT3138916T/pt unknown
- 2012-05-25 HU HUE19179871A patent/HUE064492T2/hu unknown
- 2012-05-25 HU HUE16193340 patent/HUE044772T2/hu unknown
- 2012-05-25 ES ES12726374.7T patent/ES2615737T3/es active Active
- 2012-05-25 CN CN201280037472.3A patent/CN103717742B/zh active Active
- 2012-05-25 ES ES19179871T patent/ES2968455T3/es active Active
- 2012-05-25 WO PCT/EP2012/059792 patent/WO2012163810A1/en active Application Filing
- 2012-05-25 HU HUE12726374A patent/HUE030823T2/en unknown
- 2012-05-25 HU HUE12724950A patent/HUE037126T2/hu unknown
- 2012-05-25 WO PCT/EP2012/059805 patent/WO2012163817A2/en active Application Filing
- 2012-05-25 BR BR112013030396A patent/BR112013030396A2/pt not_active IP Right Cessation
- 2012-05-25 HR HRP20231749TT patent/HRP20231749T1/hr unknown
- 2012-05-25 KR KR1020137034795A patent/KR102014502B1/ko active Active
- 2012-05-25 EP EP19179871.9A patent/EP3564378B1/en active Active
- 2012-05-25 EA EA201391548A patent/EA030898B1/ru not_active IP Right Cessation
- 2012-05-25 DK DK12726374.7T patent/DK2714911T3/en active
- 2012-05-25 PT PT127263747T patent/PT2714911T/pt unknown
- 2012-05-25 SI SI201230868A patent/SI2714911T1/sl unknown
- 2012-05-25 FI FIEP19179871.9T patent/FI3564378T3/fi active
- 2012-05-25 JP JP2014511899A patent/JP5952390B2/ja active Active
- 2012-05-25 PT PT127249506T patent/PT2714910T/pt unknown
- 2012-05-25 ES ES16193340T patent/ES2743442T3/es active Active
-
2013
- 2013-11-21 IL IL229529A patent/IL229529B2/en unknown
-
2016
- 2016-02-11 US US15/041,924 patent/US9644024B2/en active Active
- 2016-06-09 JP JP2016114910A patent/JP2017012160A/ja active Pending
- 2016-06-28 US US15/194,937 patent/US10093722B2/en active Active
-
2017
- 2017-01-20 HR HRP20170094TT patent/HRP20170094T1/hr unknown
- 2017-02-03 CY CY20171100158T patent/CY1118599T1/el unknown
- 2017-02-16 SM SM201700110T patent/SMT201700110B/it unknown
- 2017-03-21 US US15/464,454 patent/US10377816B2/en active Active
-
2018
- 2018-02-15 CY CY20181100188T patent/CY1119916T1/el unknown
- 2018-02-23 HR HRP20180339TT patent/HRP20180339T1/hr unknown
-
2019
- 2019-07-17 HR HRP20191291TT patent/HRP20191291T1/hr unknown
- 2019-08-27 CY CY20191100909T patent/CY1121936T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119916T1 (el) | Ανοσογονικη συνθεση | |
| AR125326A2 (es) | Composiciones de neisseria meningitidis y métodos de las mismas | |
| TN2017000085A1 (en) | Polypeptide having a polyester degrading activity and uses thereof | |
| UA110806C2 (uk) | Мікобактеріальна антигенна композиція | |
| MX360208B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX363136B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX360211B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| NZ599259A (en) | Mycobacterial vaccines | |
| EA033386B1 (ru) | Рекомбинантные иммуногенные полипептиды стеблевого домена гемагглютинина вируса гриппа а и их применение | |
| PH12016500377B1 (en) | Polypeptide for the hydrolytic cleavage of zearalenone and/or zearalenone derivatives, isolated polynucleotide thereof, and additive containing polypeptide, use of said polypeptide and method | |
| PH12017501520B1 (en) | Fusarium toxin-cleaving polypeptide variants, additives containing same, use of same, and method for splitting fusarium toxins | |
| MX2016002937A (es) | Vacuna oncologica. | |
| CY1118856T1 (el) | Εμβολιο pcsk9 | |
| UA108778C2 (xx) | Протираковий злитий протеїн | |
| AR094275A1 (es) | COMPOSICION INMUNOGENICA QUE COMPRENDE LA PROTEINA CDTb DE CLOSTRIDIUM DIFFICILE | |
| GB201206070D0 (en) | Clostridium difficile antigens | |
| WO2015107363A3 (en) | Mycobacterial antigen composition | |
| BR112017018703A2 (pt) | peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno | |
| PH12017502323B1 (en) | Novel xylanase | |
| MX362058B (es) | Péptido pntx(19) sintético, composición farmacéutica y uso. | |
| MX376994B (es) | Péptido c-terminal de acetilcolinesterasa cíclico para usarse en el tratamiento o la prevención de cáncer o metástasis. | |
| MY166516A (en) | Tomm34 peptides and vaccines including the same | |
| EA201590431A1 (ru) | Пшеница с новыми аллелями rht-b1 | |
| CA2868057C (en) | Epsilon toxin epitopes from clostridium perfringens with reduced toxicity | |
| AR082160A1 (es) | Anticuerpos monoclonales dirigidos contra la toxina tetanica |